Immunoproteasome-IN-2
Immunoproteasome-IN-2 is selective immunoproteasome inhibitor with IC50 = 232.3 nM for LMP7, IC50 = 9384.9 nM for β5. Immunoproteasome-IN-2 exhibits ancillary inhibitory activity against LMP2 and MECL-1 subunits. Immunoproteasome-IN-2 demonstrates anti-inflammatory efficacy in a mouse model of arthritis and shows a favorable safety profile in toxicological studies with reduced hepatotoxicity and hematotoxicity. Immunoproteasome-IN-2 has LMP7/β5 selectivity directly correlated with lower systemic toxicity. Immunoproteasome-IN-2 can be employed for research in arthritis[1].
Product Specifications
UNSPSC
12352005
Target
Proteasome
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Smiles
O=C(N[C@H](C(N[C@H](C(N[C@H](C([C@@]1(OC1)C)=O)CC2=CCCCC2)=O)[C@@H](C3=CC=C(N=C3)OC)O)=O)CO)C45CC(CC5)CC4
Molecular Formula
C32H44N4O8
Molecular Weight
612.71
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Human Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) ELISA Kit
